Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Lamifiban efficacy demonstrated in PARAGON trial

Nov. 10, 1997

Preclinical and clinical profile of Searle's fibrinogen antagonist

Nov. 10, 1997

TP-9201 covered by new U.S. patent

Nov. 10, 1997

Fibrinogen antagonists from Merck & Co.

Nov. 10, 1997

Spotlight on thrombin inhibitors

Nov. 10, 1997

ReoPro cleared in U.S. for expanded labeling

Nov. 7, 1997

Saruplase efficacy demonstrated in large patient study

Nov. 7, 1997

PEG-hirudin compared to established antithrombotic agents

Nov. 7, 1997

Akzo Nobel prepares two series of thrombin inhibitors

Nov. 7, 1997

Lefradafiban: oral prodrug for profound and sustained inhibition of platelet aggregation

Nov. 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...